Bionnovation has entered the U.S. market with a portfolio of biomaterials for regenerative dentistry that includes Bionnovation Allo, Bionnovation Oss XB, and Bionnovation Gide XP. According to the company, the products are intended to provide general practitioners with accessible options that can be incorporated into regenerative procedures and existing practice workflows. Bionnovation is a brand of the Geistlich Group and has more than three decades of experience developing and manufacturing biomaterials for regenerative dentistry.
Bionnovation Allo is a human allograft implant line for repairing, replacing, and reconstructing bone in daily dental procedures. According to the company, it is offered in multiple graft types and volume options. Each implant is processed using the Cancelle SP® Sterilization Process to ensure sterility. Cancelle SP is a registered trademark of RTI Surgical, Inc. d/b/a Evergen.
Bionnovation Oss XB is a xenograft available in small granules and multiple fill quantities. According to Bionnovation, a patented purification process preserves the material's natural bone structure, porosity, and topography. The company describes Oss XB as a biomimetic, regulatory-certified alternative to conventional xenografts that supports clinical workflows and regenerative performance.
Bionnovation Gide XP is a thin, flexible collagen membrane. According to the company, it incorporates Geistlich technology and is designed for use in daily regenerative procedures with an emphasis on simplifying clinical workflows.
“With Bionnovation, we are bringing solutions to the US market to make everyday regeneration easy,” says William Weber, global director of business development. “The new line helps dentists to integrate regenerative procedures efficiently and reliably into their daily practice.”
According to Bionnovation, its entry into the U.S. is part of the brand’s international development, with the product line positioned for general practitioners seeking accessible and economically balanced regenerative options.
Bionnovation was founded in Brazil in 1993 and develops and manufactures biomaterials for regenerative dentistry. Its products are established in more than 20 countries, according to the company. The brand is now part of the Geistlich Group.
The U.S. portfolio consists of the human-derived Bionnovation Allo allograft bone substitute, the ready-to-use Bionnovation Oss XB xenograft bone substitute, and the Bionnovation Gide XP collagen membrane. According to the company, the products are designed to integrate into existing general practice workflows without specialist-level setup and are available directly through the Bionnovation eShop.
